Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Healsea® Isotonic Nasal Spray in the Prevention of Upper Respiratory Tract Infections With Nasal Symptoms in Adults: a Pre-market Study

NCT06613906 is registered in ClinicalTrials.gov with Lallemand Pharma AG as lead sponsor.

NCT NCT06613906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06613906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Healsea® Isotonic Nasal Spray in the Prevention of Upper Respiratory Tract Infections With Nasal Symptoms in Adults: a Pre-market Study
Lead sponsor
Lallemand Pharma AG
Phase
Not applicable
Overall status
Completed
Start date
November 29, 2024
Completion date
April 28, 2025
Enrollment
198 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects (hs)